动脉瘤
医学
改良兰金量表
蛛网膜下腔出血
优势比
置信区间
内科学
队列
逻辑回归
神经重症监护
格拉斯哥结局量表
心脏病学
外科
格拉斯哥昏迷指数
麻醉
缺血
缺血性中风
作者
Andrew M. Naidech,Nazli Janjua,Kurt T. Kreiter,Noeleen Ostapkovich,Brian‐Fred Fitzsimmons,Augusto Parra,Christopher Commichau,E. Sander Connolly,Stephan A. Mayer
出处
期刊:Archives of neurology
[American Medical Association]
日期:2005-03-01
卷期号:62 (3): 410-410
被引量:356
标识
DOI:10.1001/archneur.62.3.410
摘要
Background
Aneurysm rebleeding has historically been an important cause of mortality after subarachnoid hemorrhage (SAH). Objective
To describe the frequency and impact of rebleeding in the modern era of aneurysm care, which emphasizes early surgical or endovascular treatment. Design
Inception cohort. Setting
Tertiary care medical center. Patients
A total of 574 patients enrolled in the Columbia University SAH Outcomes Project between August 1996 and June 2002. Early aneurysm repair was performed whenever feasible. Main Outcome Measures
Rebleeding was defined by prespecified clinical and radiographic criteria, excluding prehospital, intraprocedural, and postrepair events. Functional outcome was assessed at 3 months with the modified Rankin Scale. Multiple logistic regression was used to identify predictors of rebleeding, poor functional outcome, and mortality. Results
Rebleeding occurred in 40 (6.9%) of the 574 patients; most cases (73%) occurred within 3 days of ictus. Hunt-Hess grade on admission (odds ratio [OR], 1.92 per grade; 95% confidence interval [CI], 1.33-2.75;P<.001) and maximal aneurysm diameter (OR, 1.07/mm; 95% CI, 1.01-1.13;P = .005) were independent predictors of rebleeding. After controlling for Hunt-Hess grade and aneurysm size, rebleeding was associated with a markedly reduced chance of survival with functional independence (modified Rankin Scale score, ≤4; OR, 0.08; 95% CI, 0.02-0.34) at 3 months. Conclusions
Despite an aggressive management strategy, rebleeding still occurred in 6.9% of patients and was associated with a dismal outcome. Poor Hunt-Hess grade and larger aneurysm size are related to rebleeding. Pharmacologic therapy to reduce the risk of rebleeding before aneurysm repair, particularly in patients with poor grade neurologic status and large aneurysms, deserves renewed attention.
科研通智能强力驱动
Strongly Powered by AbleSci AI